Chimerix to Present at Future Leaders in the Biotech Industry Conference
Research Triangle Park, NC, March 29, 2010 – Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch, Chief Operating Officer, will present a corporate overview at the upcoming Future Leaders in the Biotech Industry conference on April 8, 2010, at 1:30 p.m. The conference is being held at the Millennium Broadway Hotel in New York City.
Mr. Moch will discuss the company’s technology assets and pipeline, including CMX001, a broad-spectrum antiviral in Phase 1 and 2 clinical trials for the treatment of BK virus and cytomegalovirus in immunocompromised transplant patients, and CMX157, being developed as a potential once-weekly nucleoside analogue against HIV infections.
Hosted by BioCentury and Thomson Reuters, Future Leaders in the Biotech Industry showcases companies best positioned to provide market leadership in the biotech industry.
About Chimerix
Chimerix is developing antiviral therapeutics to treat life-threatening diseases. Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead compound, CMX001, is in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients. CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release. CMX157, a late-stage preclinical candidate, is a new chemical entity created by applying Chimerix’s PIM (Phospholipid Intramembrane Microfluidization) conjugation technology to chemically modify tenofovir, an approved HIV drug. CMX157 is being developed as a potential once-weekly nucleoside analogue against HIV infections. Building on the company’s extensive chemical library, Chimerix is also pursuing translational medicine efforts to address malaria, dengue fever and other public health needs. Chimerix has received financing from leading venture capital firms, including Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, as well as significant funding from the National Institute of Allergy and Infectious Diseases. Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix.com.